0.0001  -0.005 (-98%)		11-07 16:00
Open: 0.0001 High: 0.0001 Volume: 300		Pre. Close: 0.0001 Low: 0.0001 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	0	1-year :	0
Resists	First :	0	Second :	0
Pivot price	0
Supports	First :	0	Second :	0
MAs	MA(5) :	0	MA(20) :	0
	MA(100) :	0	MA(250) :	0.01
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	66.6	D(3) :	88.8
RSI	RSI(14): 45
52-week	High :	0.11	Low :	0

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PXMD ] has closed above bottom band by 32.3%. Bollinger Bands are 1548.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	0 - 0	0 - 0
Low:	0 - 0	0 - 0
Close:	0 - 0	0 - 0

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.

Fri, 13 Jun 2025
PaxMedica Renames to Kuvatris, Cancels Shares - TipRanks

Fri, 04 Apr 2025
PaxMedica announces board resignations amid transition - Investing.com

Tue, 07 May 2024
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy - Yahoo Finance

Sat, 04 May 2024
PXMD Stock Price and Chart — OTC:PXMD - TradingView

Wed, 22 Nov 2023
Penny Stocks To Buy? 5 To Watch Right Now - PennyStocks.com

Thu, 22 Jun 2023
PaxMedica Comments on Common Stock Volatility - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: OTC
Sector: Healthcare
Industry: Biotechnology
Shares Out	8 (M)
Shares Float	7 (M)
Held by Insiders	12.6 (%)
Held by Institutions	0 (%)
Shares Short	638 (K)
Shares Short P.Month	552 (K)

EPS	68.22
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.15
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-258.3 %
Return on Equity (ttm)	-975.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-11 (M)
Levered Free Cash Flow	-5 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-0.01

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.